WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) presented significant clinical findings at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The data from two randomized ...
Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.
Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results